Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics.Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
